Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Not Confirmed
Not Confirmed
29-31 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Industry Trade Show
Not Confirmed
29-31 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
23 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/21/3118625/0/en/iTeos-Therapeutics-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-10-047-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html
29 May 2025
// BIOSPACE
28 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/28/3089457/0/en/iTeos-Therapeutics-Announces-Its-Intention-to-Wind-Down-Operations.html
14 May 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/iteos-gsk-discontinue-lung-cancer-therapy-development-2025-05-13/
13 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/13/3080020/0/en/iTeos-Reports-Topline-Interim-Results-from-GALAXIES-Lung-201-Study-of-Belrestotug-Dostarlimab-in-First-Line-PD-L1-High-Non-Small-Cell-Lung-Cancer-Patients.html
28 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/28/3069675/0/en/iTeos-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html
Details:
GSK4057190 (dostarlimab) in combination with GSK4428859A (belrestotug) is currently being evaluated for the treatment of advanced/metastatic non-small-cell lung cancer.
Lead Product(s): Belrestotug,Dostarlimab,Nelistotug
Therapeutic Area: Oncology Brand Name: GSK4428859A
Study Phase: Phase IIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2025
Lead Product(s) : Belrestotug,Dostarlimab,Nelistotug
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos Shares Interim Results of Belrestotug Combo in PD-L1+ NSCLC Patients
Details : GSK4057190 (dostarlimab) in combination with GSK4428859A (belrestotug) is currently being evaluated for the treatment of advanced/metastatic non-small-cell lung cancer.
Product Name : GSK4428859A
Product Type : Antibody
Upfront Cash : Inapplicable
May 13, 2025
Details:
The net proceeds from the financing are used to advance the clinical development of EOS-448 (belrestotug) in combination with GSK6097608 and Dostarlimab for non-small cell lung cancer.
Lead Product(s): Belrestotug,Dostarlimab,GSK6097608
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIProduct Type: Antibody
Sponsor: RA Capital Management
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 05, 2024
Lead Product(s) : Belrestotug,Dostarlimab,GSK6097608
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : RA Capital Management
Deal Size : $120.0 million
Deal Type : Public Offering
iTeos Therapeutics Announces $120 Million Registered Direct Offering
Details : The net proceeds from the financing are used to advance the clinical development of EOS-448 (belrestotug) in combination with GSK6097608 and Dostarlimab for non-small cell lung cancer.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Undisclosed
October 05, 2024
Details:
EOS-448 (belrestotug, TIGIT antibody) with dostarlimab is being investigated for previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos Reports Positive Objective Response Rate in GALAXIES Lung-201 Study
Details : EOS-448 (belrestotug, TIGIT antibody) with dostarlimab is being investigated for previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
September 14, 2024
Details:
The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase II/ Phase IIIProduct Type: Antibody
Sponsor: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration August 07, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,075.0 million
Deal Type : Collaboration
iTeos Doses First Patient in GALAXIES Lung-301 Phase 3, Earns $35M from GSK
Details : The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : $625.0 million
August 07, 2024
Details:
EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.
Lead Product(s): EOS-984
Therapeutic Area: Oncology Brand Name: EOS-984
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 04, 2024
Lead Product(s) : EOS-984
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos Presents EOS-984 Preclinical Data Showing T Cell Activity Restoration
Details : EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.
Product Name : EOS-984
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2024
Details:
Antibody combination, EOS-448 (belrestotug) with dostarlimab is being investigated in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 17, 2024
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
iTeos and GSK Launch Phase 3 Study on Belrestotug and Dostarlimab in Lung Cancer
Details : Antibody combination, EOS-448 (belrestotug) with dostarlimab is being investigated in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
June 17, 2024
Details:
In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions.
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IIProduct Type: Antibody
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2022
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune syst...
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
August 04, 2022
Details:
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.
Lead Product(s): Belrestotug
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2021
Details : Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : Inapplicable
October 04, 2021
Details:
The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Lead Product(s): Belrestotug,Dostarlimab
Therapeutic Area: Oncology Brand Name: EOS-448
Study Phase: Phase IProduct Type: Antibody
Sponsor: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration June 14, 2021
Lead Product(s) : Belrestotug,Dostarlimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,075.0 million
Deal Type : Collaboration
GSK Pays Up Big for Rights To TIGIT-Targeted Cancer Immunotherapy from Iteos
Details : The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Product Name : EOS-448
Product Type : Antibody
Upfront Cash : $625.0 million
June 14, 2021
Details:
The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.
Lead Product(s): EOS-850
Therapeutic Area: Oncology Brand Name: EOS-850
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 24, 2020
Lead Product(s) : EOS-850
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $100.0 million
Deal Type : Public Offering
Phase 1/2 oncology biotech iTeos Therapeutics files for a $100 million IPO
Details : The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.
Product Name : EOS-850
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2020
ABOUT THIS PAGE